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Long-Term Safety and Efficacy of Belimumab in Patients With
Systemic Lupus Erythematosus
A Continuation of a Seventy-Six–Week Phase III Parent Study in the United States
Richard A. Furie,1 Daniel J. Wallace,2 Cynthia Aranow,3 James Fettiplace,4 Barbara Wilson,5
Prafull Mistry,6 David A. Roth,7 and David Gordon7
Objective. We undertook this US multicenter continuation study (GlaxoSmithKline study BEL112233;
ClinicalTrials.gov identifier: NCT00724867) to assess
long-term safety and efficacy of belimumab in patients
with systemic lupus erythematosus (SLE) who completed
the Study of Belimumab in Subjects with SLE 76-week
trial (ClinicalTrials.gov identifier: NCT00410384).
Methods. Patients continued to receive the same
belimumab dose plus standard therapy; patients previously receiving placebo received 10 mg/kg belimumab.
The primary outcome measure was long-term safety of
belimumab (frequency of adverse events [AEs] and
damage assessed using the Systemic Lupus International
Collaborating Clinics/American College of Rheumatology
Damage Index [SDI], evaluated every 48 weeks [1 study
year]). Other assessments included the SLE Responder

Index (SRI), flare rates (using the modified SLE Flare
Index [SFI]), prednisone use, and B cell levels.
Results. Of 268 patients, 140 completed the study
and 128 withdrew. The mean  SD score on the Safety of
Estrogens in Lupus Erythematosus National Assessment
version of the SLE Disease Activity Index (SELENA–
SLEDAI) at baseline was 7.8  3.86. The mean  SD
SDI score increased by 0.4  0.68 from its value at baseline (1.2  1.51). The overall incidence of treatmentrelated and serious AEs remained stable or declined
through study year 7. An SRI response was achieved by
41.9% and 75.6% of patients at the study year 1 and
study year 7 midpoints, respectively. At the study year 7
midpoint, relative to baseline, 78.2% had achieved a ≥4point reduction in the SELENA–SLEDAI score, 98.4%
had no new British Isles Lupus Assessment Group
(BILAG) A organ domain score and no more than 1 new
BILAG B organ domain score, 93.7% had no worsening
in the physician’s global assessment of disease activity,
20.6% had experienced ≥1 severe SFI flare, the mean
decrease in prednisone dose was 31.4%, and the median
change in CD20+ B cell numbers was 83.2%.
Conclusion. These long-term exposure results
confirm the previously observed safety and efficacy
profiles of belimumab in patients with SLE.
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Systemic lupus erythematosus (SLE) is a chronic
autoimmune disorder that affects a number of organ systems (1) and causes a marked impairment in quality of life
(QoL) (2,3). Active disease (4,5) and medication toxicities
contribute to the accrual of long-term organ damage
(6–8). Corticosteroids and immunosuppressant drugs have
demonstrated clinical benefits (9); however, concerns
remain about the safety of their long-term use (6–8).
Belimumab is a human IgG1k monoclonal antibody licensed for the treatment of adult patients with
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active, autoantibody-positive SLE who are receiving
standard therapy. Belimumab binds to and inhibits the
activity of soluble human B lymphocyte stimulator protein (10). A placebo-controlled phase II study showed
that intravenous (IV) belimumab plus standard therapy
was generally well tolerated (11); a good safety profile
was maintained over 7 years (12). Two phase III studies,
the Study of Belimumab in Subjects with SLE 52-week
(BLISS-52) and 76-week (BLISS-76) trials, demonstrated
the safety and efficacy of belimumab in patients with
autoantibody-positive, active SLE (13,14). The long-term
safety and efficacy of belimumab were examined in 2
open-label continuation studies (GlaxoSmithKline [GSK]
studies BEL112233 and BEL112234) in patients who completed the BLISS studies. A pooled interim analysis of
these 2 long-term continuation studies demonstrated low
rates of organ damage accrual in patients with moderateto-severe SLE, and safety over 5 years of exposure (15).
Herein, we present the clinical results of the complete
BLISS-76 continuation study BEL112233 conducted in
US-only patients. Due to the study design, all non-US
patients in BLISS-76 and BLISS-52 entered the rest-ofworld continuation study BEL112234 (ClinicalTrials.gov
identifier: NCT00712933).
The objectives of this continuation study were to
provide continuing treatment to patients who completed BLISS-76 and evaluate the long-term safety and
tolerability, impact on QoL, and efficacy of belimumab
treatment in patients with SLE. The long-term impact
of belimumab on QoL in patients with SLE will be
reported separately.
PATIENTS AND METHODS
Study design. This was a multicenter, continuation
study (GSK study BEL112233; ClinicalTrials.gov identifier:
NCT00724867) conducted in patients who completed the 76week phase III parent study BLISS-76 (GSK study
BEL110751; ClinicalTrials.gov identifier: NCT00410384) in
the US (14). In BLISS-76, patients were randomized to
receive 1 mg/kg belimumab IV, 10 mg/kg belimumab IV, or
placebo, plus standard therapy for 76 weeks (14). Patients
who previously received placebo received 10 mg/kg belimumab in the continuation study. Patients randomized to
receive belimumab continued to receive the same dose as in
the parent study (1 or 10 mg/kg IV every 28 days) plus standard therapy. Following a protocol amendment (March 9,
2011), patients receiving 1 mg/kg belimumab had their dose
increased to 10 mg/kg. Data on all patients receiving belimumab during this study were pooled for analysis.
To be eligible for enrollment, patients had to have
completed BLISS-76 through week 72 and be able to receive
the first dose of belimumab within 4 weeks (minimum 2
weeks, maximum 8 weeks). Patients were excluded if in the
investigator’s opinion they presented with clinical evidence of
uncontrolled, acute, or chronic disease not due to SLE. Other
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key exclusion criteria included occurrence of an adverse event
(AE) in the parent trial that would place the patient at undue
risk, or laboratory abnormalities.
Since the study was designed to have 48-week study
years, study years do not align with calendar years. The study
was designed to end either after 5 calendar years from the
date of enrollment of the last patient or when fewer than 100
patients remained in the trial, whichever occurred first. The
study was conducted from August 5, 2008 to March 26, 2015,
and up to 8 calendar years of data were collected (maximum
exposure 2,908 days) (Figure 1).
Clinical site personnel remained blinded with regard
to parent study treatment until results of the parent study
were made public. The study was performed in accordance
with the Declaration of Helsinki (16). All sites maintained
ethics committee and institutional review board approval, and
written informed consent was obtained from all patients.
Study end points. The primary objective of this study
was the evaluation of the long-term safety of belimumab, as
assessed by AEs, AEs of special interest, vital signs, and clinical
laboratory tests (hematology, chemistry, routine urinalysis, and
immunogenicity testing). Organ damage was assessed using the
Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index (SDI) (17). Assessments were performed at week 24 (study year midpoint) and
week 48 (study year end, referred to hereafter as study year).
AEs were monitored throughout the study and for 8 weeks following the last dose of belimumab. Clinical laboratory assessments were performed on day 0, at weeks 4, 12, 24, 36, and 48 of
study year 1, and at weeks 24 and 48 of each study year thereafter. Organ damage was assessed every 48 weeks.
Efficacy and biomarker assessments were exploratory.
The primary efficacy assessment was the SLE Responder
Index (SRI) (18) response rate, a validated composite end
point defined as a ≥4-point reduction from baseline in the
Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index (SELENA–
SLEDAI) score (19), no worsening in the physician’s global
assessment of disease activity on a 0–10-cm visual analog
scale (<0.3 points from baseline), and no new British Isles
Lupus Assessment Group (BILAG) A or no more than 1 new
BILAG B organ domain score (20).
Other efficacy assessments included the SELENA–
SLEDAI, BILAG, physician’s global assessment of disease activity, flare rates, prednisone use, and biomarkers. Flare rates were
assessed by the SLE Flare Index (SFI) (19) and the BILAG. SFI
flare rates (mild/moderate or severe) were defined by the modified SELENA–SLEDAI SFI (the modified SFI excludes severe
flares that were triggered only by an increase in the SELENA–
SLEDAI score to >12) (21). BILAG flare was defined by at least
1 new BILAG A organ domain score or >1 new BILAG B organ
domain score compared with baseline (21). Biomarker assessments included anti–double-stranded DNA (anti-dsDNA) levels,
serum complement levels, proteinuria values, serum Ig levels,
and B cell subsets. Patients with a baseline SELENA–SLEDAI
score of <4 at entry into the continuation study were excluded
from the SRI analysis. Efficacy and biomarker assessments were
performed every 24 weeks from the first dose of belimumab,
with the exception of serum Ig levels, which were tested at week
24 and week 48 during study year 1 and then every 48 weeks.
Concomitant corticosteroids were converted to a prednisone
equivalent average daily dose (mg/day).
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Figure 1. Disposition of the systemic lupus erythematosus (SLE) patients and enrollment by treatment in the Study of Belimumab in Subjects
with SLE 76-week (BLISS-76) trial. This continuation study (GlaxoSmithKline [GSK] study BEL112233) was designed to end either after 5 calendar years from the date of enrollment of the last patient or when fewer than 100 patients remained in the trial, whichever occurred first. Patients
at non-US sites were not eligible for enrollment into this study and had the opportunity to enroll in another open-label, long-term continuation
study, GSK study BEL112234. For patients who received placebo in the parent study (BLISS-76; GSK study BEL110751), baseline was the last
assessment prior to their first dose of belimumab, at the start of the continuation study. For patients who received belimumab in the parent study,
baseline was the latest assessment prior to commencing the parent study. One patient who withdrew from the continuation study reported an
adverse event (AE) leading to discontinuation, but the investigator-recorded reason for withdrawal was “physician decision.”

Post hoc analyses were carried out for several parameters of interest. Baseline disease characteristics were examined for patients who withdrew and those who completed the
study, to investigate completer bias. Withdrawals among SRI
responders were reported, and severe flares were examined
according to which severe SFI flare criteria were met. In
addition, the proportions of patients who experienced normalization of anti-dsDNA and complement levels and who
discontinued prednisone during the study were examined.
Statistical analysis. No formal statistical hypothesis
testing was performed, and all analyses were descriptive and
exploratory. Analyses included those patients enrolled in the
continuation study who received at least 1 dose of belimumab.
Patients who received 1 mg/kg or 10 mg/kg belimumab in the
parent study were pooled for all analyses. Baseline was defined
as the last assessment prior to the first dose of belimumab (day
0). Therefore, baseline for the parent study placebo group was
the last assessment prior to their first dose of belimumab, at
the start of the continuation study. For patients receiving active

treatment in the parent study, baseline was the latest assessment prior to commencing the parent study, BLISS-76.
AEs from both the parent and continuation studies
were coded according to the Medical Dictionary for Regulatory Activities, version 17.1. All AE data were summarized by
study year according to the recorded start date of the AE.
AEs that continued for >1 study year were reported in the
year they first occurred; repeat AE episodes were reported in
the year they reappeared. If the AE onset date was missing,
it was assumed the start date was study year 1. If the AE end
date was missing, it was assumed the AE continued until
study end. AEs of special interest included malignant neoplasms, postinfusion systemic reactions, infections, depression,
suicide, and self-injury. Continuous variables were summarized, reporting mean and SD, median and 25th and 75th
percentile, and minimum and maximum. Categorical variables were summarized with frequency counts and percentages. All analyses were performed using SAS software,
version 9.3.
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RESULTS
Patient population. The modified intent-to-treat
(ITT) population comprised 268 patients (46.5% of
parent study completers; non-US patients in the parent
study were not eligible for this study); 140 patients
(52.2%) completed the continuation study, and 128
patients (47.8%) withdrew. The majority of patients
were white (186 of 268 [69.4%]) and female (250 of
268 [93.3%]), with a mean  SD age of 42.8  11.33
years (Table 1). The duration of SLE ranged from 0 to
36 years, with a mean  SD of 7.7  6.77 years. The
majority of patients (188 of 268 [70.1%]) entered the
continuation study with a baseline SELENA–SLEDAI
score of ≤9 and a mean  SD SDI of 1.2  1.51. The
mean  SD duration of belimumab exposure was
1,962.1  746.44 days, with a median of 2,166.5 days
(range 28–2,908).
The number of patients withdrawing from the
study each year remained consistent throughout the study,
and the number of patients starting each yearly interval
declined at similar rates among patients initially treated
with belimumab in the parent study and those treated
with placebo (see Supplementary Figure 1, available on
the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.40439/abstract). The 3
most common reasons for withdrawal were withdrawal by
patient (31 of 128 [24.2%]), AE (25 of 128 [19.5%]), and
other (22 of 128 [17.2%]) (Figure 1). A post hoc review
of the data indicated that where a reason was provided
for withdrawal by patient, the 2 requests most often cited
were a desire to conceive and logistical reasons (data not
shown). The majority of patients (11 of 14) who withdrew
due to lack of efficacy did so in the first 4 years of the
study. Disease flares were a commonly cited reason for
withdrawal due to lack of efficacy (5 of 14 patients).
Baseline characteristics of patients who withdrew
from the study and of those who completed were examined post hoc. The mean  SD SELENA–SLEDAI
scores at baseline were 7.8  3.85 and 7.8  3.89
among those who withdrew and those who completed,
respectively. Thirty-eight of 128 patients (29.7%) who
withdrew had a SELENA–SLEDAI score of ≥10 at
baseline, compared with 42 of 140 patients (30.0%)
who completed the study. Of patients who withdrew, 91
of 128 (71.1%) had a score of >1 on the physician’s
global assessment of disease activity, compared with 98
of 140 patients (70.0%) who completed the study.
Among patients who withdrew, 63 of 128 (49.2%) had
active disease at baseline, defined as ≥1 BILAG A or
≥2 BILAG B organ domain scores, while 74 of 140
patients (52.9%) who completed the study had active
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Table 1.

Baseline characteristics of the 268 patients*

Female
Age, mean  SD years
BMI, mean  SD kg/m2
Race
White
Black or African American/African heritage
Asian
SLE disease duration, mean  SD years
SELENA–SLEDAI score (0–105), mean  SD
SELENA–SLEDAI score
≤9
≥10
Complement levels
Low C3 and/or low C4
No low C3 or C4
PGA (0–10-cm VAS), mean  SD
SDI score (0–47), mean  SD
SLE Flare Index
At least 1 flare
At least 1 severe flare
BILAG organ domain involvement†
Concomitant medications
Corticosteroids only
Immunosuppressant drugs only
Antimalarials only
Average prednisone dose
0 mg/day
>0 to ≤7.5 mg/day
>7.5 to ≤40 mg/day

250 (93.3)
42.8  11.33
28.4  7.43
186 (69.4)
57 (21.3)
13 (4.9)
7.7  6.77
7.8  3.86
188 (70.1)
80 (29.9)
119 (44.4)
149 (55.6)
1.19  0.60
1.2  1.51
65 (24.3)
2 (0.7)
137 (51.1)
21 (7.8)
11 (4.1)
41 (15.3)
95 (35.4)
87 (32.5)
86 (32.1)

* Except where indicated otherwise, values are the number (%). BMI =
body mass index: SLE = systemic lupus erythematosus; SELENA–
SLEDAI = Safety of Estrogens in Lupus Erythematosus National
Assessment version of the SLE Disease Activity Index; PGA = physician’s global assessment of disease activity; VAS = visual analog scale;
SDI = Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index.
† At least 1 new British Isles Lupus Assessment Group (BILAG) A
organ domain score or >1 new BILAG B organ domain score compared with baseline.

disease at baseline. At baseline, ≥1 SFI flare had been
experienced by 28 of 128 patients (21.9%) who then
withdrew and by 37 of 140 patients (26.4%) who completed. Among patients who withdrew, 2 of 128 (1.6%)
experienced ≥1 severe flare prior to baseline; no
patients who completed the study had a severe flare
prior to baseline. Twenty-three of 128 patients (18.0%)
who withdrew from the study had proteinuria >0.5 gm/
24 hours at baseline, compared with 13 of 140 (9.3%)
who completed. Low C3/C4 levels (C3 <0.9 gm/liter
and/or C4 <0.16 gm/liter) at baseline were reported in
52 of 128 patients (40.6%) who withdrew and 67 of 140
(47.9%) who completed. Overall, baseline disease characteristics between patients who withdrew and those
who completed were similar.
Safety. AEs. At least 1 AE was experienced by
267 of 268 patients (99.6%), and 145 of 268 patients
(54.1%) had an AE that was considered by the investigator to be drug-related (Table 2). Discontinuation
of belimumab due to an AE occurred in 26 of 268
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Incidence of treatment-emergent AEs by study year*

At least 1 AE
At least 1 treatment-related AE†
At least 1 serious AE
Serious AEs by system organ class‡
Infections and infestations
Musculoskeletal and
connective tissue
At least 1 severe AE
Severe AEs by system organ class‡
Infections and infestations
Musculoskeletal and
connective tissue
At least 1 AE resulting in study
agent discontinuation
All infections of special interest§
Serious
Opportunistic infections of
special interest¶
Serious
All herpes zoster
Opportunistic¶
Serious
Malignant neoplasms (excluding
nonmelanoma skin cancer)
Postinfusion systemic reactions#
Any depression/suicide/self-injury§
Deaths

Any time
postbaseline
(n = 268)

Year 0–1
(n = 268)

Year 1–2
(n = 259)

Year 2–3
(n = 244)

Year 3–4
(n = 219)

Year 4–5
(n = 202)

Year 5–6
(n = 192)

Year 6–7
(n = 130)

Year 7+
(n = 65)

267 (99.6)
145 (54.1)
112 (41.8)

260 (97.0)
89 (33.2)
33 (12.3)

235 (90.7)
55 (21.2)
30 (11.6)

206 (84.4)
40 (16.4)
25 (10.2)

184 (84.0)
35 (16.0)
22 (10.0)

167 (82.7)
30 (14.9)
24 (11.9)

145 (75.5)
32 (16.7)
16 (8.3)

87 (66.9)
13 (10.0)
13 (10.0)

31 (47.7)
3 (4.6)
3 (4.6)

44 (16.4)
22 (8.2)

13 (4.9)
7 (2.6)

9 (3.5)
5 (1.9)

4 (1.6)
3 (1.2)

6 (2.7)
2 (0.9)

8 (4.0)
4 (2.0)

7 (3.6)
2 (1.0)

2 (1.5)
1 (0.8)

1 (1.5)
0

100 (37.3)

31 (11.6)

19 (7.3)

23 (9.4)

21 (9.6)

18 (8.9)

15 (7.8)

10 (7.7)

3 (4.6)

28 (10.4)
23 (8.6)

7 (2.6)
9 (3.4)

2 (0.8)
4 (1.5)

4 (1.6)
4 (1.6)

7 (3.2)
1 (0.5)

6 (3.0)
5 (2.5)

3 (1.6)
3 (1.6)

0
1 (0.8)

1 (1.5)
0

26 (9.7)

3 (1.1)

4 (1.5)

7 (2.9)

8 (3.7)

0

2 (1.0)

2 (1.5)

0

43 (16.0)
5 (1.9)
16 (6.0)

14 (5.2)
1 (0.4)
3 (1.1)

13 (5.0)
1 (0.4)
3 (1.2)

8 (3.3)
1 (0.4)
4 (1.6)

6 (2.7)
0
0

7 (3.5)
1 (0.5)
3 (1.5)

11 (5.7)
1 (0.5)
6 (3.1)

6 (4.6)
0
2 (1.5)

0
0
0

0
27 (10.1)
9 (3.4)
1 (0.4)
10 (3.7)

0
9 (3.4)
1 (0.4)
0
0

6
2
1
1

0
(2.3)
(0.8)
(0.4)
(0.4)

0
4 (1.6)
2 (0.8)
0
4 (1.6)

0
4 (1.8)
0
0
2 (0.9)

0
5 (2.5)
2 (1.0)
0
0

0
7 (3.6)
5 (2.6)
0
0

0
3 (2.3)
2 (1.5)
0
2 (1.5)

0
0
0
0
1 (1.5)

50 (18.7)
73 (27.2)
2 (0.7)

23 (8.6)
25 (9.3)
0

11 (4.2)
22 (8.5)
1 (0.4)

7 (2.9)
17 (7.0)
0

5 (2.3)
6 (2.7)
1 (0.5)

4 (2.0)
8 (4.0)
0

6 (3.1)
3 (1.6)
0

5 (3.8)
4 (3.1)
0

1 (1.5)
1 (1.5)
0

* Values are the number (%) of patients. Patients reporting multiple adverse events (AEs) within a study year are only counted once in each of
the appropriate categories.
† Possibly, probably, or definitely related.
‡ Two most frequently occurring AE system organ classes presented.
§ Per custom Medical Dictionary for Regulatory Activities (MedDRA) query.
¶ Per adjudication by GlaxoSmithKline.
# Per custom MedDRA query, broad search.

patients (9.7%), with the majority (n = 22) of these
occurring in the first 4 years of the study. With the
exception of intraductal proliferative breast lesion (n =
2), all AEs that led to study drug discontinuation were
different. The most common AEs (occurring in ≥25%
of patients) were arthralgia (108 of 268 [40.3%]), nausea (88 of 268 [32.8%]), headache (86 of 268 [32.1%]),
and infections, including bacterial upper respiratory
tract infection (77 of 268 [28.7%]), viral upper respiratory tract infection (76 of 268 [28.4%]), and bacterial
urinary tract infection (70 of 268 [26.1%]). At least 1
serious AE was reported in 112 of 268 patients
(41.8%), and at least 1 severe AE (grade 3 or grade 4
events listed as life-threatening) was reported in 100 of
268 patients (37.3%). Two deaths occurred (0.7%); neither was considered study drug–related (hypertensive
heart disease, polydrug toxicity [later adjudicated as
suicide]). AEs of special interest are summarized in
Table 2. Sixteen patients acquired an opportunistic
infection (none categorized as serious), and 3 incidents

of suicidal behavior (1.1%) were reported. Overall, the
incidence of AEs, treatment-related AEs, serious AEs,
and severe AEs remained stable or declined from study
year 1 to study year 7+.
Clinical laboratory evaluations and vital signs.
Lymphocyte count was the only hematologic measure in
which ≥10% of patients had either grade 3 or grade 4
values during the study; 50 of 177 patients (28.2%) had
a grade 3 value. The percentage of patients who had at
least a 2-grade shift from baseline in clinical chemistry
studies (liver function, electrolytes, and other chemistry
studies) was generally stable or declined over time, not
exceeding 12% postbaseline. The percentage of patients
with grade 3 or grade 4 values at any time postbaseline
did not exceed 5% for any clinical chemistry parameter
or urinalysis, and no trends of clinical concern were
noted. During the study, 7 of 268 patients (2.6%) had a
grade 3 value for IgG, and none of these patients experienced a serious or severe infection. Two patients had a
persistent positive anti-human antibody response that
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occurred during at least 2 consecutive assessments or
once at the final assessment, although no patient had >2
consecutive positive results. Mean diastolic and systolic
blood pressures were stable over time.
Organ damage. The mean  SD SDI score was
1.2  1.51 at baseline. At study year 7 the mean  SD
SDI score had increased by 0.4  0.68.
Efficacy. SRI response. An SRI response had
been achieved by 96 of 229 patients (41.9%) and 90 of
119 patients (75.6%) overall at the study year 1 and
study year 7 midpoints, respectively (Figure 2A). Withdrawals between these 2 time points were examined
post hoc, along with the occurrence of new responses,
to account for the decrease in absolute number of
responders. Of the patients who withdrew (113 of 268;

873

modified ITT population) between these 2 time points,
34 of 113 (30.1%) were responders at the study year 1
midpoint. Of the 90 patients who were SRI responders
at the study year 7 midpoint, 35 of them (38.9%) had
not been responders at the study year 1 midpoint (52
patients [57.8%] were responders at the study year 1
midpoint).
SELENA–SLEDAI score. The overall percentage
of patients with a ≥4-point reduction from baseline in
the SELENA–SLEDAI score increased from 44.4%
(104 of 234 patients) to 78.2% (93 of 119 patients) at
the study year 1 and study year 7 midpoints, respectively (Figure 2B). The overall mean  SD percentage
reduction from the baseline SELENA–SLEDAI score
(7.8  3.86) increased from 27.1  48.29% at the study

Figure 2. Efficacy end points. A, Systemic Lupus Erythematosus Responder Index (SRI) response. B, Safety of Estrogens in Lupus Erythematosus
National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index (SELENA–SLEDAI) score. C, British Isles Lupus
Assessment Group (BILAG) score. In A and B, patients with baseline SELENA–SLEDAI scores of <4 were excluded from the analyses. No new
A/2B scores = no new BILAG A organ domain score and no more than 1 new BILAG B organ domain score. D, Physician’s global assessment of
disease activity (PGA) score. Y1W24 = year 1, week 24.
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year 1 midpoint (n = 252) to 64.9  37.46% at the
study year 7 midpoint (n = 125).
BILAG worsening. At baseline, the percentage of
patients with at least 1 BILAG A or 2 BILAG B organ
domain scores was 51.1% (137 of 268). Overall, at each
visit, ≥95% of patients had no new BILAG A organ
domain score and no more than 1 new BILAG B
organ domain score. At the study year 1 midpoint, 258
of 265 patients (97.4%) had no new BILAG A organ
domain score and no more than 1 new BILAG B
organ domain score. This remained stable throughout
the study, with 125 of 127 patients (98.4%) meeting this
criterion at the study year 7 midpoint (Figure 2C).
Among patients with a postbaseline flare assessment, 33
of 267 (12.4%) and 84 of 267 (31.5%) had at least 1
BILAG flare by the study year 1 and study year 7 midpoints, respectively.
Worsening in physician’s global assessment of disease activity. The overall percentage of patients with no
new worsening (increase of <0.30 points) from baseline
in the physician’s global assessment of disease activity
was ≥89% up to the study year 7 midpoint visit (119 of
127 patients [93.7%]) (Figure 2D).
SFI flare. By the study year 1 midpoint, 149 of 267
patients (55.8%) had experienced at least 1 SFI flare,
and 15 of 267 (5.6%) had experienced at least 1 severe
flare. Up to and including the study year 7 midpoint visit,
these percentages increased to 92.5% (247 of 267) and
20.6% (55 of 267), respectively (cumulative). Of the 55
patients with a severe flare at the study year 7 midpoint,
new/worse severe symptoms were experienced by 23.6%
of patients (13 of 55), 63.6% of patients (35 of 55) had
an increase in daily prednisone dose to >0.5 mg/kg, and
38.2% of patients (21 of 55) had 1 new medication for
SLE activity. An increase to a score of ≥2.5 on the physician’s global assessment of disease activity was recorded
in 5 of 55 patients (9.1%), and 10 of 55 patients (18.2%)
were hospitalized for SLE activity.
Prednisone use. Among patients receiving concomitant prednisone (n = 77), the mean decrease from
baseline in prednisone dose at the study year 7 midpoint was 31.4% (Figure 3). The percentage of patients
with a baseline prednisone dose of >7.5 mg/day whose
dose was reduced to ≤7.5 mg/day was 50.0% (32 of 64)
at the study year 3 midpoint, 39.5% (15 of 38) at study
year 7, and 58.3% (7 of 12) at study year 8. Some
patients (23 of 173 [13.3%]) discontinued prednisone
permanently during the study (post hoc analyses).
Biomarkers. At baseline, 135 of 268 patients
(50.4%) were anti-dsDNA positive (≥30 IU/ml), 86 of
268 (32.1%) had low C3 levels, and 98 of 268 (36.6%)
had low C4 levels. Post hoc analyses showed that
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Figure 3. Mean percentage change from baseline in prednisone dose.
Y1W24 = year 1, week 24.

among those who were anti-dsDNA positive at baseline, levels in 23 of 135 (17.0%) normalized during the
study, while levels in 10 of 86 (11.6%) with low C3 and
levels in 20 of 98 (20.4%) with low C4 normalized.
Overall, mean levels of anti-dsDNA antibodies decreased by 44.1% (n = 123) from baseline to study year
7 (Table 3), and mean C3 and C4 levels increased by
18.9% (n = 123) and 50.0% (n = 123), respectively.
Among the 36 patients with elevated baseline
proteinuria (>0.5 gm/24 hours), mean levels in 14
patients improved by 69.1% from baseline to the study
year 7 midpoint. Normal levels were achieved by 11 of
34 of these patients (32.4%) at the study year 1 midpoint and by 9 of 14 of these patients (64.3%) at the
study year 7 midpoint.
IgG levels decreased by 29.0% (n = 112) from
baseline to study year 7. The median percentage change
from baseline in CD20+ B cells was 83.22% (n = 107)
at the study year 7 midpoint (Table 3). Reductions were
also observed for CD19+, naive, activated, plasma, SLE
subset, and plasmacytoid B cells. The median percentage change from baseline in memory B cells was
87.65% (n = 244) at the study year 1 midpoint and
67.18% (n = 106) at the study year 7 midpoint.
Although variable over time, the median percentage
change from baseline in short-lived plasma B cells was
47.50% (n = 114) at the study year 7 midpoint.
DISCUSSION
Long-term treatment with belimumab was associated with a stable or decreased incidence of AEs and
sustained efficacy across 7 study years of exposure, similar to the safety and efficacy profiles of belimumab

Biomarker

1.103  0.296/253
0.220  0.101/253
0.28  0.666/251
1.17  1.534/34
12.93  4.704/252
69.00 (36.00, 113.00)/
253
68.00 (35.00, 113.0)/
251
36.00 (16.00, 64.00)/
251
131.00 (72.00, 206.00)/
247
30.00 (14.00, 55.00)/
251
31.00 (12.00, 69.00)/
251
13.00 (6.00, 34.00)/
251
13.00 (5.00, 32.00)/
247
64.00 (31.00, 108.00)/
251

1.068  0.310/268
0.198  0.099/268
0.31  0.561/268
1.36  1.013/36
15.16  6.062/268
114.00 (58.00, 191.00)/
265
112.50 (55.00, 189.00)/
262
88.00 (38.00, 155.00)/
262
190.00 (106.00, 320.00)/
257
17.00 (8.00, 28.00)/
262
41.00 (17.00, 128.00)/
261
17.00 (6.00, 45.00)/
262
16.00 (7.00, 46.00)/
258
95.00 (58.00, 182.00)/
261
29.41)/245

4.50 (1.00, 11.00)/122
9.00 (3.00, 25.00)/122
9.00 (4.00, 24.00)/122
2.00 (1.00, 5.00)/122

16.13 ( 71.43, 88.89)/243
32.29 ( 73.13, 61.54)/238
32.49 ( 73.33, 32.00)/243

6.00 (3.00, 12.00)/111

3.00 (1.00, 5.00)/122

13.00 (6.00, 24.00)/111

20.00 (10.00, 36.00)/111

18.50 (8.00, 34.00)/122

10.09  3.745/112†

0.15  0.170/120
0.41  0.368/14

1.226  0.311/123
0.250  0.101/123

78.50  292.110/123

Study year 7
midpoint
(observed)

37.20 ( 66.75, 27.50)/244

87.65 (27.43, 167.54)/244

33.35 ( 65.19, 36.11)/240

55.56 ( 73.74,

31.82 ( 56.40, 9.15)/245

32.56 ( 57.58, 5.88)/250

12.80  14.078/252

10.44  84.097/251
17.51  81.675/34

6.74  26.443/253
19.82  38.678/253

7.61  19.068/253

Study year 1
midpoint (% change
from baseline)

73.68)/118

47.06)/106

96.45)/116

73.53)/107

69.05)/107

68.73)/120

98.00 ( 99.61,

94.22)/117

47.50 ( 79.17, 41.67)/114

50.00 ( 81.44, 28.57)/117

92.31 ( 98.05,

67.18 ( 80.00,

98.85 ( 99.62,

87.39 ( 92.77,

83.22 ( 89.24,

82.73 ( 89.01,

28.97  16.733/112†

11.26  75.237/120
69.09  25.846/14

18.90  30.975/123
49.96  96.800/123

44.07  148.281/123

Study year 7
midpoint (% change
from baseline)

* Values are the mean  SD/number of patients or median (interquartile range)/number of patients. Anti-dsDNA = anti–double-stranded DNA; SLE = systemic lupus erythematosus.
† Study year 7 end.

SLE subset
(CD19+CD27brightCD38bright)
Short-lived plasma
(CD19+CD20 CD27high/+)
Plasmacytoid (CD20+CD138+)

Plasma (CD20 CD138+)

Memory (CD20+CD27+)

Activated (CD20+CD69+)

Naive (CD20+CD27 )

CD20+

78.53  67.774/253

Study year 1
midpoint
(observed)

88.10  73.565/268

Observed value
at baseline

Biomarkers observed at baseline and change from baseline (modified intent-to-treat population)*

Anti-dsDNA, IU/ml
Complement level, gm/liter
C3
C4
Proteinuria level, gm/24 hours
All patients
Patients with >0.5 gm/24 hours
at baseline
IgG, gm/liter
B cells/ll
CD19+

Table 3.
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previously established during studies of patients with
SLE (12–14,22). In the present study, three-fourths of
patients were SRI responders at the study year 7 midpoint, an observation that is consistent with the
phase II continuation study, in which 65% of patients
had achieved an SRI response by study year 7 (73% in
the completer analysis) (12).
Secondary analyses of the BLISS studies have
shown that patients treated with belimumab (plus standard therapy) experienced reduced rates of severe flares
when compared with those receiving placebo (plus standard therapy) (13,14). In the BLISS-52 and BLISS-76
studies, rates of severe SFI flare were 14% (40 of 290
patients) and 21% (56 of 273 patients), respectively
(13,14), among patients who received 10 mg/kg belimumab. In this continuation study, the percentage of
patients experiencing a new severe SFI flare between
the study year 1 and study year 7 midpoints was low;
the cumulative count increased from 15 of 267 patients
(5.6%) to 55 of 267 patients (20.6%) during this period.
In the phase II continuation study, the percentages of
severe flares were also low, decreasing from 7% to 2%
across each year of belimumab treatment (12).
Organ damage accrual in this continuation study
was low when compared with prospective SLE inception
cohorts measuring damage accrual (23–25), with a mean
increase in SDI of 0.4 over 7 study years. However,
while observational cohorts included the full spectrum
of patients, the BLISS studies excluded patients with
severe lupus nephritis and central nervous system disease (13,14), manifestations that may result in higher
rates of damage accrual (26,27). These exclusions, in
addition to treatment with belimumab, could account, in
part, for the reported lower rates of organ damage.
One of the major goals of SLE therapy is to
reduce corticosteroid exposure (28). In the current
study, mean prednisone dose decreased over time, and
approximately one-eighth of patients were able to discontinue prednisone.
Quantitative analysis of B cell phenotypes performed in this study represents the first evaluation of longterm changes in B cells in response to belimumab
treatment. The results presented are consistent with those
of a small 2-year study that investigated the effects of belimumab treatment on levels of B cell subsets (29). Over the
duration of the study, there was a decrease in levels for the
majority of B cell subsets, but no subsets were completely
depleted. As demonstrated in that earlier study (29), memory B cells were initially found to increase in response to
belimumab, while a decrease was seen after study year 1.
There are several limitations to the interpretation
of these data, primarily the open-label design with no

FURIE ET AL

placebo control group. In addition, selection bias could
have been responsible for enriching the study population
with patients more likely to respond well to treatment
over time. Furthermore, approximately one-third of the
study population was treated with placebo during the
parent study. Since these patients continued to receive
placebo (and standard therapy) for 76 weeks before
entering this extension study, they may have entered this
extension study with more benign disease (32% of
patients in the placebo arm withdrew from the parent
study). However, the post hoc analysis did not indicate
an imbalance in SLE disease activity or characteristics at
baseline between those who withdrew over the course of
the study and those who completed. In addition, the
decline in the number of patients starting each yearly
interval was similar between patients initially treated
with belimumab in the parent study and those treated
with placebo. Withdrawals from the study were more
prevalent among nonresponders, although the reasons
for withdrawal among nonresponders cannot be confirmed. The impact of the withdrawals may have created
responder bias by affecting the composition of the
remaining study population.
Although the duration of treatment with belimumab 10 mg/kg differed (depending on initial treatment
assignment), all treatment groups were pooled for analysis. In addition, low numbers of patients for some analyses, particularly at later time points, may confound
interpretation. Data on AEs of special interest, particularly rates of infection, should be interpreted with caution,
as fewer patients contributed to the denominator in later
intervals.
This study demonstrates the long-term benefits
of belimumab in addition to standard therapy in
patients with active SLE. Belimumab was well tolerated, and patients benefited from an overall decrease
in disease activity. Moreover, prednisone use declined,
and accrual of organ damage was low.
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